Pfizer Unit Wins $107.5M Patent Verdict Against AstraZeneca

By Bonnie Eslinger · May 17, 2024, 8:26 PM EDT

A Delaware federal jury on Friday said that AstraZeneca Pharmaceuticals LP should pay $107.5 million in royalty damages for infringing a Pfizer-brand cancer treatment patent, although a final decision won't be issued...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Puma Biotechnology, Inc. v. AstraZeneca Pharmaceuticals LP et al

Case Number

Court

Delaware

Nature of Suit

Patent

Date Filed

September 22, 2021

Recent Articles By Bonnie

October 11, 2024
9th Circ. Backs Planned Parenthood's $14M Atty Fee Win
October 03, 2024
Texas Transgender Health Rule Suit Paused For Gov't Appeal
October 02, 2024
Lab Co. Settles Bogus Testing Claims With Feds For $27M
August 28, 2024
Del. Justices OK Mid-Case Appeal In Zantac Class Suit
August 16, 2024
States Get Teva Generic Price-Fix Case On Docket As 1st Trial
August 09, 2024
DC Circ. Pans Suit Claiming HHS Caused Health Aid Shortage
June 28, 2024
Texas Justices Back Ban On Gender Affirming Care For Minors
June 28, 2024
Jury Convicts Seattle Doctor In NBA Health Fraud Case
March 22, 2024
Expert's Sanctions Off Limits In SEC's 'Shadow Trading' Trial
March 11, 2024
Acadia Investors Get Class Cert. In Suit Over Parkinson's Drug